Christian G. Downs, JD, MHA, discusses his thoughts on how rebuilding the 340B program should be addressed, Medicare Payment Advisory Commission’s Part B cost control proposals, and the potential for progress in tackling rising drug costs.
Keeping patients on their oral oncology medications involves a combination of active management, record keeping, and coordination among healthcare workers, pharmacy professionals explained during a panel discussion.
Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
The molecular profile of a patient with cancer who is about to be treated for their metastatic disease is the most critical piece of information you can have for that patient, according to Howard A. “Skip” Burris III, MD.
Leah Ralph discusses the ACCC’s position on the ACA repeal bill, the Medicare Payment Advisory Commission’s (MedPAC) Part B cost control proposals, and the possibility for comprehensive reform on the 340B Drug Discount Program.
An April report from COA stated that PBMs have been calling patients and urging them to get their drugs from PBM-owned pharmacy networks, rather than through physician dispensaries. At this year’s Community Oncology Conference, presentations and discussions focused on this report.
Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.